Jason Westin, MD FACP
@lymphoma_doc
Professor, Director of Clinical Research, Section Chief Aggressive Lymphoma @MDAndersonNews, past chair of @ASCO government relations committee, Opinions mine
ID: 1080058020
http://faculty.mdanderson.org/Jason_Westin/Default.asp 11-01-2013 15:40:10
7,7K Tweet
6,6K Followers
2,2K Following
Chemo-free Approaches to Lymphoma: Jason Westin, MD, Wyndham H. Wilson, and Gerald R. Crabtree will address this topic in a plenary at the AACR International Meeting on Advances in Malignant Lymphoma (June 19-22, Philadelphia). bit.ly/3y9odOf #AACRlymph24 Jason Westin, MD FACP
Jason Westin, Christopher Melani, and Gerald R. Crabtree discussed "Chemo-free Approaches to Lymphoma" in a plenary session at the AACR International Meeting on Advances in Malignant Lymphoma. #AACRlymph24 Jason Westin, MD FACP Christopher Melani Jason Westin, MD
Thank you to AACR, Margaret Foti, PhD, MD (hc), Blood Cancer Discovery and International Conference on Malignant Lymphoma for supporting #aacrlymph24, and for all that attended. It was a great opportunity for interaction and idea exchange to drive lymphoma research forward. Looking forward to the next meeting in 2 years. Pencil it in! #lmsm
Cancer drug shortage ends - national supply of the cancer drug cisplatin now exceeds demand, per Dr. Robert M. Califf - thanks to ASCO Julie Gralow Jason Westin, MD FACP Ashley Love Sumrall, MD, FACP, FASCO and many others who have advocated strongly to overcome these issues 🙌#advocacy beckershospitalreview.com/pharmacy/cance…
I was honored to speak at the NRG Oncology Summer Symposium Next and New Treatments today about the promise of CAR T-cell therapy. Although it hasn’t changed practice yet in #gynsm cancers, it has in heme malignancies. The future for immunotherapy is bright!
Rly excited to share this ASCO piece in my new series "Profiles in Advocacy " highlighting Oncologists from all over the U.S. Here's Dr Najera's story who I met at #ASCOadvocacysummit Yes community oncology voices matter connection.asco.org/blogs/profiles… Ashley Love Sumrall, MD, FACP, FASCO Jason Westin, MD FACP
Join me in honoring Michael Frumovitz by donating to a special @GYNcancer award that will support young investigators interested in GYN Tumor research. He was an incredible physician and an absolutely exceptional human being. Read more about his impact here …el-frumovitz-memorial.raiselysite.com
We are thrilled to have you join our MD Anderson Cancer Center team!
A rad week at #ASHCRTI with didactic lectures, lunch breakout sessions, small group discussions, biostatistician & librarian office hours, and much more. The highlight is the beach cookout with the #bestsmallgroupever! Nadine Abdallah Surbhi Sidana, MD @Ore Odejide MD Monica G
Great week at ASH Clinical Research Training Institute. Congrats to our rising stars - the future is bright! ⭐️🌟⭐️ Follow: Seda Tolu Laura Samples, MD Zulfa Omer Yun Kyoung Ryu #ASHCRTI
#Hematology: w/ Carla Casulo, MD we 🗣️ the current SoC/landscape for #DLBCL (RCHOP, Pola, CART, BiTEs) Full discussion: - cancernetwork.com/treatment-algo… - Oncbrothers.com/dlbcl-2024 - Also on the “Oncology Brothers” podcast #HemeTwitter #MedTwitter #OncTwitter CancerNetwork® #lymsm
Glad to see @ASCCAN Lisa Lacasse make the case for removing financial barriers to clinical trials. #ASCOadvocacy has long advocated for these changes & is working to help expand access to clinical trials so anyone who wants to enroll is able to. More: society.asco.org/sites/new-www.…
Listening to some of my favorite Texans tonight at #SOHO24 #SOHO2024 #CARTcell #mmsm #lymsm #AMLsm #leusm Jason Westin, MD FACP Larry Anderson,MD,PhD,FACP Naval Daver, M.D. Tapan Kadia
CONGRESS | #SOHO2024 Jason Westin Jason Westin, MD FACP MD Anderson Cancer Center shares data from the phase Ib trial of GOLCA+R-CHOP as 1L therapy in aggressive B-cell #lymphoma. ORR 0.2mg 82% and 0.4mg 88%, uMRD 0.2mg 73% and 0.4mg 90%, median DoR NR in either group, 12-mo PFS 0.4mg 85%, 120-mo
I'm incredibly honored & very grateful to my former boss & mentor Robert Z. Orlowski whose guidance and support have been instrumental in my journey. I owe much of this achievement to your leadership and belief in me. Excited for the path ahead as we continue advancing care for MM pts!